A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia

A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia

Highlights • In this study, the MTD for Len in combination with intermediate dose AraC was 10 mg. • The most prominent toxicities from this combination were rash and liver toxicity. • The ORR on this study was 41% (13/32), comprised of CR (5), CRi(5) and HI (3). • Response to Len/AraC in r/r AML was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia research 2016-04, Vol.43, p.44-48
Hauptverfasser: Griffiths, Elizabeth A, Brady, William E, Tan, Wei, Vigil, Carlos E, Thompson, James E, Ford, Laurie A, Dickey, Noelle M, Bashaw, Heather, Sperrazza, Jill, Wetzler, Meir, Wang, Eunice S
Format: Artikel
Sprache:eng
Schlagworte:
Acute myeloid leukemia
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Clinical trial
Cytarabine
Cytarabine - administration & dosage
Cytarabine - adverse effects
Disease-Free Survival
Female
Hematology, Oncology and Palliative Medicine
Humans
Lenalidomide
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - mortality
Male
Middle Aged
Phase I
Relapse/refractory AML
Survival Rate
Thalidomide - administration & dosage
Thalidomide - adverse effects
Thalidomide - analogs & derivatives
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • In this study, the MTD for Len in combination with intermediate dose AraC was 10 mg. • The most prominent toxicities from this combination were rash and liver toxicity. • The ORR on this study was 41% (13/32), comprised of CR (5), CRi(5) and HI (3). • Response to Len/AraC in r/r AML was not substantially better that single agent AraC
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2016.02.003